COVID-19 Vaccines Came off Production lines at CanSino’s New Production Base

On April 25, vaccines rolled out at Phase III Production Base launched by CanSino Biologics in TEDA. The single-dose vaccine is the only recombinant novel coronavirus vaccine (Adenovirus Type 5 Vector) that has gained market approval in China so far. The vaccine will guarantee the prevention and control of new and sudden major infectious diseases.

Guests visit the vaccine production workshop of CanSino Biologics Inc.

A technician works at the vaccine production workshop of CanSinoBIO.